Anti-Human CD59 (Protectin) FITC

Grouped product items
Size Price Qty
100 tests
$340.00

Additional OV9A2 Formats

Cat.No. Format Starting From
11611-60 PE $ 170.00
11611-50 FITC $ 340.00
Catalog Number : 11611-50

description

The OV9A2 monoclonal antibody specifically reacts with human CD59 (Protectin), a 19-25 kDA GPI-anchored glycoprotein. CD59 is expressed on hematopoietic and non-hematopoietic cells including lymphocytes, granulocytes, erythrocytes, monocytes and neurons. CD59 can inhibit complement cytolytic activity and the assembly of the membrane attack complex when bound to C8 and C9 complement components. It is involved in T cell activation and modulates T cell adhesion through interaction with CD2.

Additional Information

Clone:
OV9A2
Format:
FITC
Applications:
FC
Reactivity:
Human
Isotype:
Mouse IgG1, kappa
Research Interest: Innate Immunity
Cell Type: B Cells, T Cells
Application: FC
Clone: OV9A2
Preparation:
The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.
Formulation:
Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.
References:

Deckert, M., Kubar, J., Zoccola, D., Bernard‐Pomier, G., Angelisova, P., Horejsi, V., & Bernard, A. (1992). CD59 molecule: a second ligand for CD2 in T cell adhesion. European journal of immunology22(11), 2943-2947.

Korty, P. E., Brando, C. L. A. R. A., & Shevach, E. M. (1991). CD59 functions as a signal-transducing molecule for human T cell activation. The Journal of immunology146(12), 4092-4098.

Davies, A., Simmons, D. L., Hale, G., Harrison, R. A., Tighe, H., Lachmann, P. J., & Waldmann, H. (1989). CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. The Journal of experimental medicine170(3), 637-654.

© BioGems International, Inc. All rights reserved.